Hemorrhage on the surface of cancellous bone presents a significant challenge in orthopedic surgery. Traditional bone wax, commonly utilized for hemostasis in bone wounds, is non-absorbable and associated with various complications, including pseudarthrosis, paralysis, venous sinus thrombosis, chronic inflammation, allergic reactions, and infections, thereby limiting its clinical utility. In contrast, absorbable bone wax, primarily composed of medical-grade water-soluble polymer materials, exhibits excellent biocompatibility. It is fully absorbed, excreted, or eliminated by the body without leaving toxic residues. This study employs a rigorous efficacy design to select an appropriate patient cohort for lumbar fusion surgery, based on specific inclusion and exclusion criteria. Participants are randomly assigned to either an experimental group receiving absorbable bone wax or a control group receiving traditional bone wax, facilitating a randomized, open-label, parallel-controlled clinical trial. This study aims to evaluate the comparative effects of absorbable bone wax versus traditional bone wax on the rate of bone fusion following hemostasis of bone wounds. The objective is to furnish robust evidence-based insights into the application of absorbable bone wax for bone wounds necessitating fusion, thereby establishing a safe, effective, and broadly applicable technique for bone wound hemostasis in clinical practice.
Participants must be aged between 18 and 75 years, with no restrictions on gender.
Participants with conditions such as single-segment lumbar intervertebral disc protrusion, lumbar spondylolisthesis, and lumbar spinal stenosis who are scheduled to undergo posterior decompression, intervertebral fusion, and internal fixation surgery.
Participants must be able to comprehend the objectives of the study, willingly participate, and provide informed consent by signing the consent form.
Individuals with a hemorrhagic predisposition or coagulation disorders, indicated by a prothrombin time (PT) of 18 seconds or greater, and those with a history of prolonged anticoagulant use.
Individuals presenting with lumbar spine infections or fractures.
Individuals with known allergies to materials such as polyethylene glycol, sodium carboxymethyl cellulose, and bone wax (including beeswax, paraffin, and isopropyl palmitate).
Individuals whose conditions are critical, making it challenging to accurately assess the efficacy and safety of the equipment.
Parallel
Absorbable bone wax for hemostasis in the osteotomy surface of the facet joint
DeviceFollowing the enrollment of patients who underwent posterior lumbar decompression, intervertebral bone graft, and internal fixation surgery, a "V-shaped" osteotomy was executed at the facet joint contralateral to the decompression site, with 0.5g absorbable bone wax subsequently applied to the osteotomy surface.
Traditional bone wax for hemostasis in the osteotomy surface of the facet joint
DeviceFollowing the enrollment of patients who underwent posterior lumbar decompression, intervertebral bone graft fusion, and internal fixation surgery, a "V-shaped" osteotomy was executed at the facet joint contralateral to the decompression site, with 0.5g traditional bone wax subsequently applied to the osteotomy surface.
The clinical fusion rate of lumbar facet joints
The proportion of individuals achieving the clinical fusion standard of the facet joint was assessed within each group. Six months postoperatively, the fusion status of the facet joints at the surgical segments was evaluated using continuous thin-slice CT plain scans combined with three-dimensional reconstruction images of the lumbar vertebrae. The evaluation criteria were based on the guidelines established by Ren et al. (2020) in their study on modified facet joint fusion for lumbar degenerative disease. According to these criteria, clinical fusion is confirmed when one side of the facet joint attains grade I or grade II radiological fusion standards.
The success rate of hemostasis within three minutes
The success rate of achieving hemostasis within three minutes during surgery is defined as the proportion of patients who meet the hemostatic objective within this timeframe.
Postoperative wound healing
Postoperative wound healing is assessed 14 days following the procedure, with observations including the presence of bleeding, redness, and swelling at the wound site.
Incidence of adverse events
This encompasses any adverse events associated with the use of bone wax, such as infections, inflammatory responses, and allergic reactions.
Postoperative infection rate
This metric evaluates the frequency of infections occurring in the surgical area and serves as a critical indicator of surgical safety.
Reoperation rate
This refers to the proportion of cases requiring additional surgical intervention due to unsuccessful hemostasis or other complications.
Long-term complications
This includes any complications or adverse reactions related to the use of bone wax that manifest during the extended postoperative follow-up period.
Click on the lead sponsor to view all of their trials.
Shanghai Changzheng Hospital
Lead sponsor
Fujian Medical University Union Hospital
Collaborator
Jiangxi Provincial People's Hopital
Collaborator
The First Affiliated Hospital of Nanchang University
Collaborator
Qilu Hospital of Shandong University
Collaborator
Beijing Chao Yang Hospital
Collaborator
First Affiliated Hospital of Guangxi Medical University
Collaborator
The Third Xiangya Hospital of Central South University
Collaborator
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Collaborator
Wuhan TongJi Hospital
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
